Rituximab as second-line treatment for adult immune thrombocytopenia (the RITP trial): a multicentre, randomised, double-blind, placebo-controlled trial
Open Access
- 4 February 2015
- journal article
- research article
- Published by Elsevier BV in The Lancet
- Vol. 385 (9978), 1653-1661
- https://doi.org/10.1016/s0140-6736(14)61495-1
Abstract
No abstract availableThis publication has 21 references indexed in Scilit:
- Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopeniaBlood, 2012
- A pilot randomized trial of adjuvant rituximab or placebo for nonsplenectomized patients with immune thrombocytopeniaBlood, 2012
- The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopeniaBlood, 2011
- Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopeniaBlood, 2010
- The ITP syndrome: pathogenic and clinical diversityBlood, 2009
- Is splenectomy still the gold standard for the treatment of chronic ITP?American Journal of Hematology, 2007
- Therapy with high-dose dexamethasone (HD-DXM) in previously untreated patients affected by idiopathic thrombocytopenic purpura: a GIMEMA experienceBlood, 2006
- Earlier administration of Rituximab allows higher rate of long-lasting response in adult patients with autoimmune thrombocytopeniaExperimental Hematology, 2006
- The efficacy and safety of B‐cell depletion with anti‐CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpuraBritish Journal of Haematology, 2004
- Initial Treatment of Immune Thrombocytopenic Purpura with High-Dose DexamethasoneNew England Journal of Medicine, 2003